Loading...

CTNM CONTINEUM THERAPEUTICS INC Expansion Plans 8-K Filing

CNTN

CTNM

CONTINEUM THERAPEUTICS INC

(CTNM)

2025 8-K

New Funding Agreement

New Equity Plan

Clinical Trial Update

Clinical Trial Update

Q3 Financial Results

Clinical Trial Results

Financial Statements

Management Changes

Board Appointment

Financial Results

Financial Results

External Links:

On December 8, 2025, Contineum Therapeutics, Inc. submitted details of its Phase 2 clinical trial for PIPE-791 targeting idiopathic pulmonary fibrosis, planning to enroll about 324 participants and set for completion in June 2028.

AI Assistant

CONTINEUM THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.